These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 30340519

  • 1. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
    Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA.
    Infect Dis Poverty; 2018 Oct 19; 7(1):108. PubMed ID: 30340519
    [Abstract] [Full Text] [Related]

  • 2. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
    Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J.
    PLoS Negl Trop Dis; 2014 May 19; 8(5):e2875. PubMed ID: 24854196
    [Abstract] [Full Text] [Related]

  • 3. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.
    Clin Infect Dis; 2006 Aug 01; 43(3):357-64. PubMed ID: 16804852
    [Abstract] [Full Text] [Related]

  • 4. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
    Kimutai R, Musa AM, Njoroge S, Omollo R, Alves F, Hailu A, Khalil EA, Diro E, Soipei P, Musa B, Salman K, Ritmeijer K, Chappuis F, Rashid J, Mohammed R, Jameneh A, Makonnen E, Olobo J, Okello L, Sagaki P, Strub N, Ellis S, Alvar J, Balasegaram M, Alirol E, Wasunna M.
    Clin Drug Investig; 2017 Mar 01; 37(3):259-272. PubMed ID: 28066878
    [Abstract] [Full Text] [Related]

  • 5. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, Alnour M, Shah S, Chappuis F, van Griensven J, Zachariah R.
    Trop Med Int Health; 2015 Dec 01; 20(12):1674-84. PubMed ID: 26427033
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
    Tamiru A, Mohammed R, Atnafu S, Medhin G, Hailu A.
    PLoS Negl Trop Dis; 2021 Aug 01; 15(8):e0009713. PubMed ID: 34464401
    [Abstract] [Full Text] [Related]

  • 7. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
    Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M.
    PLoS Negl Trop Dis; 2012 Aug 01; 6(6):e1674. PubMed ID: 22724029
    [Abstract] [Full Text] [Related]

  • 8. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
    Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN.
    Am J Trop Med Hyg; 2007 Jul 01; 77(1):89-94. PubMed ID: 17620635
    [Abstract] [Full Text] [Related]

  • 9. Clinical aspects of paediatric visceral leishmaniasis in North-west Ethiopia.
    Diro E, Lynen L, Gebregziabiher B, Assefa A, Lakew W, Belew Z, Hailu A, Boelaert M, van Griensven J.
    Trop Med Int Health; 2015 Jan 01; 20(1):8-16. PubMed ID: 25329449
    [Abstract] [Full Text] [Related]

  • 10. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
    Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, Davidson RN.
    Trans R Soc Trop Med Hyg; 2001 Jan 01; 95(6):668-72. PubMed ID: 11816442
    [Abstract] [Full Text] [Related]

  • 11. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C, Diro E, de Lima Pereira A, Buyze J, Stille K, Ahmed F, van Griensven J, Ritmeijer K.
    PLoS Negl Trop Dis; 2018 May 01; 12(5):e0006527. PubMed ID: 29799869
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
    Veeken H, Ritmeijer K, Seaman J, Davidson R.
    Trop Med Int Health; 2000 May 01; 5(5):312-7. PubMed ID: 10886792
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
    Mueller M, Balasegaram M, Koummuki Y, Ritmeijer K, Santana MR, Davidson R.
    J Antimicrob Chemother; 2006 Oct 01; 58(4):811-5. PubMed ID: 16916865
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN.
    Clin Infect Dis; 2011 Dec 01; 53(12):e152-8. PubMed ID: 22016502
    [Abstract] [Full Text] [Related]

  • 19. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.
    Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S.
    Trans R Soc Trop Med Hyg; 2003 Dec 01; 97(3):350-4. PubMed ID: 15228258
    [Abstract] [Full Text] [Related]

  • 20. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
    Dube A, Singh N, Sundar S, Singh N.
    Parasitol Res; 2005 Jun 01; 96(4):216-23. PubMed ID: 15868188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.